Navigation Links
Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/14/2008

BOSTON, Oct. 14 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today announced the Company's lead product, amadacycline, formerly PTK 0796, a first-in-class aminomethylcycline, will be the subject of a Late Breaker poster presentation at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). ICAAC will be held in Washington, D.C. from October 25 - October 28, 2008.

More information on the poster session at ICAAC:

Sunday, October 26, 12:15 - 1:15 pm EST

Session 126; New Treatment Options in Skin and Soft Tissue Infections

Location: Hall C

Poster: L1515B

-- Safety and Efficacy of PTK 0796: Results of the Phase 2 Study in

Complicated Skin and Skin Structure Infections Following IV and

Oral Step-down Therapy.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance. Paratek's lead compound, amadacycline, formerly PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that is being developed for the treatment of the most common and serious hospital bacterial infections, including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae). Oral and IV formulations of amadacycline were compared to Zyvox (R) in a recently completed Phase 2 clinical study in complicated skin and skin structure infections (cSSSI). In addition to amadacycline, Paratek is also developing other broad- and narrow-spectrum tetracycline antibiotics to treat hospital and community infections based on its novel tetracycline chemistry expertise.

Outsid
'/>"/>

SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
2. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
7. National Study Presented at ACG 2008 Confirms New Device Functions Like Rear-View Mirror to Provide Improved View of the Colon
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
10. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
11. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , CHICAGO, Nov. 30 Dr. Joce... and Intervention at George Washington University ...ow occult lesions identified with Breast-Specific ...lti-modality imaging for needle biopsy as well, as...l meeting of the Radiological Society of North Ame...
(Date:11/30/2009)..., , ATLANTA, Nov. 30 Amoe...urgery breast care products, is sponsoring the 4th...or the first time, Amoena will honor survivors and... by awarding a cabin for the one with the most ins...test, Amoena wants to hear about young mothers who...
(Date:11/30/2009)..., , INDIANAPOLIS, Nov. 30 /PRNewswir...ion (FDA) has approved Cymbalta® (duloxetine ...anxiety disorder (GAD) in adults, Eli Lilly and Co... generalized anxiety disorder can be a chronic ill...nts find a treatment option that is effective in b...
Breaking Medicine Technology:Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Early Bedtime May Help Stave Off Teen Depression 48337 1Early Bedtime May Help Stave Off Teen Depression 48337 2Early Bedtime May Help Stave Off Teen Depression 48337 3Herley Receives a 241 2 Million Contract Award for Complex Integrated Microwave Assemblies for U S Electronic Attack Aircraft 48334 1Herley Receives a 241 2 Million Contract Award for Complex Integrated Microwave Assemblies for U S Electronic Attack Aircraft 48334 2New study indicates radiologists need standards to ensure optimal visual accuracy 48331 1
... Combination of R7227, protease inhibitor, and R71...cant potency in reducing viral load in patients wi...if., and PRINCETON, N.J., April 25 Roche, InterMu... VRUS ) today announced the first results from t... acting antiviral (DAA) combination therapy for th...
...irst study evaluating DUROS(R) continuous delivery... , , HAYWARD, Calif., April 24 Intarcia Therapeu...nt accrual to a phase 1b clinical study evaluating...de). The study is being conducted at multiple cent...t of 44 patients with type 2 diabetes for a period...
Other Medicine Technology:Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 2Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 3Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 4Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 5Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 6Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 7Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 8Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 9Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 10Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen 11Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3
(Date:11/30/2009)... Keynote speaker & Aut...sm , Corpus Christi, TX ...as Autism Conference is set to be held in Corpus ..., December 5, 2009 at the American Bank Center., ,...nd is expected to make a nearly $300,000 economic ...
(Date:11/30/2009)..., , NEW YORK, Nov. 30 ...arch report is available in its catalogue: ,, ...cals: Emerging strategies in ingredients, pharma, ...m/p0165649/Key-Players-and-Innovative-Start-Ups-in...-pharma-food-and-drinks.html ,, Nutraceuticals...
(Date:11/30/2009)..., , WASHINGTON, Nov. 30 - Sal... A Cause" on Monday, December 7(th) to raise funds...hildhood terminal diseases. All proceeds from each...Children,s Research Hospital. ,, Salon Leau ha...ars. The salon is owned by LoAnn Lai, widely recog...
(Date:11/30/2009)..., , NASHVILLE, Tenn., Nov. 30 /PRNews...inking about gifts for the holidays. For a loved o...tia, family members and friends oftentimes struggl...nior Living , one of the leading providers of seni...heimer,s and dementia care , offers these suggesti...
(Date:11/30/2009)..., , CHICAGO, Nov. 30 Physic...on) reported today on results of a study demonstra...ary CT angiography (cCTA) by Rcadia,s COR Analyzer...nary artery stenosis in hospital emergency departm... the automated system to enhance the use of cCTA h...
Breaking Medicine News(10 mins):Health News:18th Annual Texas Autism Conference Returns To Corpus Christi, Makes Nearly $300,000 Economic Impact 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 3Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 4Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 6Health News:Georgetown Hair Salon Helps St. Jude Find A Cure 2Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3
...t Memorial Sloan-Kettering Cancer Center, New York...pression of genes for therapeutic purposes, and us... mice. , Small, noncoding RNA molecules known as ...ells known as T cells at different stages of their...
...porated,(Nasdaq: VPHM ) today announced that the...e Application (sBLA) to the U.S. Food and Drug Adm...man) as a treatment for acute attacks of,hereditar...terim data from an ongoing open,label acute study ...
...llnesses common, study shows , , MONDAY, ...re common among young adults in the United States,...reach this finding, U.S. researchers analyzed data...und that 45.8 percent of the 2,188 college student...
...ncer Institute,s cancer registry has found that as...d or incomplete radiation treatment following brea...re can lead to worse outcomes. , Dr. Heather Taff...ients aged 65 and older, almost 1,300 women experi...
...swire/ -- Americans United for Life (AUL) today ... resolution opposing the federal "Freedom of Choic...opt the resolution immediately when they convene t...rotects and promotes the abortion industry, sacrif...
...ve decline in some, study says , , MONDAY,...cise regularly have increased blood flow and more ...s. , The University of North Carolina (UNC) study,...xercise prevents cognitive decline in the elderly....
Other Medicine News:Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2Health News:Delays in radiation therapy lead to increased breast cancer recurrence 2Health News:Americans United for Life Urges State Legislatures to Oppose Federal Power Grab: Provides Model Resolution Denouncing Freedom of Choice Act (FOCA) 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: